JACC:支持用植入设备检测无症状房颤的十点理由

2015-01-28 佚名 中国循环杂志微信

随着起搏器、心脏再同步化治疗,以及植入式心律转复除颤器(ICD)等广泛进入临床,之前未确诊的心律失常特别是房颤,也被越来越多地被发现。那么如何看待这些无症状的被检测出的房颤?美国心脏学院专家会员Aman Chugh提出了以下十点认识。 1.对于伴有隐源性脑卒中的患者,植入式设备的房颤检出率要比传统的监测方式如心电图或动态心电图更高。 2、对于发生脑卒中的患者,30天内事件监测相对应

随着起搏器、心脏再同步化治疗,以及植入式心律转复除颤器(ICD)等广泛进入临床,之前未确诊的心律失常特别是房颤,也被越来越多地被发现。那么如何看待这些无症状的被检测出的房颤?美国心脏学院专家会员Aman Chugh提出了以下十点认识。

1.对于伴有隐源性卒中的患者,植入式设备的房颤检出率要比传统的监测方式如心电图或动态心电图更高。

2、对于发生脑卒中的患者,30天内事件监测相对应的房颤检出率也高于24小时Holter。

3、对于既往发生脑卒中的患者,房颤的检出有助于明确启动随后的口服抗凝治疗

4、心脏植入式电子装置特别是双腔起搏器和除颤器,由于能够进行持续监测,可谓检测心律失常的金标准。

5、心脏植入式电子装置检出亚临床房颤较为常见。

6、设备检测的“心房高频事件(AHRE)”、房性心动过速或“模式转换”等需要直接心电描记分析进行确认,以免受到外部噪音、电极断裂以及其它现象的干扰而被错判为房颤。

7、对于近期发生过血栓栓塞事件的心脏植入式电子装置患者,这些装置常会漏掉近期房颤发作。

8、对于这些由电子设备检测出的房颤,即使同时伴有脑卒中风险,但也只有少数人启动了口服抗凝治疗。

9、较之传统方式诊断的房颤患者,电子设备检出的房颤者服用抗凝药物比例较低的原因尚不清楚,可能与对存储的心电描记解释不熟悉有关。

10、尽管对于设备检出的房颤患者如何管理还缺乏明确的数据,但根据当前的危险分层方案,给予其口服抗凝治疗是合理的。

原始出处:

Chen-Scarabelli C1, Scarabelli TM2, Ellenbogen KA3, Halperin JL4.Device-Detected Atrial Fibrillation: What to Do With Asymptomatic Patients? J Am Coll Cardiol. 2015 Jan 27;65(3):281-294. doi: 10.1016/j.jacc.2014.10.045.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853313, encodeId=a1c4185331338, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 16 21:10:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032628, encodeId=4b5f2032628de, content=<a href='/topic/show?id=9f1062689bf' target=_blank style='color:#2F92EE;'>#植入设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62689, encryptionId=9f1062689bf, topicName=植入设备)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Fri May 08 15:10:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324991, encodeId=71e313249914d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484931, encodeId=6e2b148493110, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520250, encodeId=3e3d1520250b2, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-07-16 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853313, encodeId=a1c4185331338, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 16 21:10:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032628, encodeId=4b5f2032628de, content=<a href='/topic/show?id=9f1062689bf' target=_blank style='color:#2F92EE;'>#植入设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62689, encryptionId=9f1062689bf, topicName=植入设备)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Fri May 08 15:10:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324991, encodeId=71e313249914d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484931, encodeId=6e2b148493110, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520250, encodeId=3e3d1520250b2, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853313, encodeId=a1c4185331338, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 16 21:10:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032628, encodeId=4b5f2032628de, content=<a href='/topic/show?id=9f1062689bf' target=_blank style='color:#2F92EE;'>#植入设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62689, encryptionId=9f1062689bf, topicName=植入设备)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Fri May 08 15:10:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324991, encodeId=71e313249914d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484931, encodeId=6e2b148493110, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520250, encodeId=3e3d1520250b2, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853313, encodeId=a1c4185331338, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 16 21:10:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032628, encodeId=4b5f2032628de, content=<a href='/topic/show?id=9f1062689bf' target=_blank style='color:#2F92EE;'>#植入设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62689, encryptionId=9f1062689bf, topicName=植入设备)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Fri May 08 15:10:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324991, encodeId=71e313249914d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484931, encodeId=6e2b148493110, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520250, encodeId=3e3d1520250b2, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853313, encodeId=a1c4185331338, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 16 21:10:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032628, encodeId=4b5f2032628de, content=<a href='/topic/show?id=9f1062689bf' target=_blank style='color:#2F92EE;'>#植入设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62689, encryptionId=9f1062689bf, topicName=植入设备)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Fri May 08 15:10:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324991, encodeId=71e313249914d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484931, encodeId=6e2b148493110, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520250, encodeId=3e3d1520250b2, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Jan 30 00:10:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-01-30 jiyangfei

相关资讯

房颤患者在口服华法林过程中发生脑卒中 怎么办?

近期碰到一例患有多年房颤的病人口服华法林抗凝治疗,前几日出现四肢乏力麻木,行走受限,在急诊行头颅CT提示脑梗死可能。患者及家属颇感疑惑:“医生说华法林是预防脑梗的,已经服用华法林,为什么还会发生脑梗死?”许多患者都知道,房颤最大的危害在于脑卒中,防止脑卒中发生的关键在于根治房颤,因此,不少阵发和部分持续房颤患者行射频消融治疗。而对于已经持续多年的房颤患者而言,手术成功率较低,多数患者依赖于抗凝药物

控制房颤心室率的药物知多少

在以往多期的文章中,我们曾详细介绍过房颤的射频消融及抗凝治疗。尽管对于房颤患者最理想的治疗莫过于恢复窦性心律,但对于左房内径过大(一般大于55mm)、合并没有纠正的二尖瓣狭窄及其它器质性心脏病的房颤来说复律成功的比率不高,或者即使复为窦性心律也很难维持,这种情况下可退而其次应用药物减慢较快的心室率以改善症状。今天,小编就带领大家简单了解一下这类药物。 β受体阻滞剂为临床中控制房颤心室率最

研究:肥胖增房颤风险

古人言:腰带长,寿命短,一胖百病缠。肥胖对健康的影响越来越受到人们的关注。那么如何判断肥胖呢?这里推荐一个简单的方法,体重指数法。体重指数(BMI)的计算公式:BMI=体重(Kg)/身高(m)2BMI<25为正常,25≤BMI<30为超重,BMI≥30为肥胖。 有研究表明肥胖与房颤之间存在相关性。该研究共入选的5282例受试者,研究者根据体重指数(BMI)将入选者分为正常体重组、超重组和

Ann Intern Med:应警惕大出血和血栓栓塞风险

英国和丹麦联合研究表明,在房颤患者中,应用非类固醇类抗炎药(NSAID)为大出血和血栓栓塞的独立危险因素。短期应用NSAID亦与出血风险升高相关。论文11月18日发表于《内科学年鉴》杂志。 研究纳入1997-2011年间房颤住院患者150900例,中位年龄75岁,47%为女性。利用考克斯(Cox)模型评估NSAID与抗血栓治疗期间大出血和血栓栓塞的绝对风险。共有53732例(35.6%)

房颤患者卒中预防风险CHA2DS2-VASc评分公式

房颤患者卒中预防风险CHA2DS2-VASc评分公式

Circulation AE:地高辛增加房颤患者的死亡率和住院率

地高辛是从植物洋地黄中提取出的药物,已用于控制房颤患者的心率超过100年,在全世界广泛使用。但是支持该用法的数据有限并且有研究发现使用地高辛出现不良后果。因此研究者进行试验研究地高辛和房颤患者(没有心衰症状)死亡率和住院率的关系。研究者Anthony Steimle说:“我们的研究表明在现代临床实践中使用地高辛治疗房颤需要重新评价。”考虑到有其他控制心率的方法,使用地高辛治疗房颤时要特别慎重,特别